The FDA’s regulatory power is in question after a Supreme Court decision limiting federal agencies’ ability to interpret ambiguous statutes. This could lead to legal challenges for the FDA and create uncertainty for drug and device companies. While the decision may not affect the FDA’s main task of approving drugs and devices, it could impact other regulatory efforts. Industry experts predict destabilization and a lack of predictability in the regulatory system. This decision could have a significant impact on the industry and may lead to more legal challenges for the FDA in the future. Industries may face more uncertainty than before.
Source link
Court’s Chevron ruling could cause headaches for drug industry
